Chaojun Liu
Yi Zhang
1 Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;
2 Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;
3 Engineering Key Laboratory for Cell Therapy of Henan Province, Zhengzhou 450052, China
Funds: This study was supported by grants from the National Natural Science Foundation of China (Grant Nos. 81171986, and 81271815), Research Grant from the Ministry of Public Health (No. 201501004), the National Key Research and Development Program of China (2016YFC1303501), Major Science and Technology Projects of Henan Province (1611003101000).
Received Date: 2016-10-31
Rev Recd Date:2016-12-16
Abstract
Abstract
T-cell receptor (TCR)-engineered T cells are a novel option for adoptive cell therapy used for the treatment of several advanced forms of cancer. Work using TCRengineered T cells began more than two decades ago, with numerous preclinical studies showing that such cells could mediate tumor lysis and eradication. The success of these trials provided the foundation for clinical trials, including recent clinical successes using TCRengineered T cells to target New York esophageal squamous cell carcinoma (NY-ESO-1). These successes demonstrate the potential of this approach to treat cancer. In this review, we provide a perspective on the current and future applications of TCR-engineered T cells for the treatment of cancer. Our summary focuses on TCR activation and both pre-clinical and clinical applications of TCR-engineered T cells. We also discuss how to enhance the function of TCR-engineered T cells and prolong their longevity in the tumor microenvironment.Keywords: T-cell receptor,
tumor antigen,
TCRengineered T cells,
neoantigen,
tumor microenvironment
PDF全文下载地址:
http://www.protein-cell.org/article/exportPdf?id=90c0cf77-da99-4e39-b2ac-aaa4c72f0aef&language=en
